First experiment study in cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer following neoadjuvant chemohormonotherapy

Background. Nowadays there is no consensus on application of cytoreductive prostatectomy in a complex therapy in patients with oligo-metastatic prostate cancer.

Study objective: assessment of short-term results of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer.

Materials and methods. Cytoreductive prostatectomy was performed in 7 patients with oligometastatic prostate cancer.

Results. Postoperative complications in 3 (42.9 %) out of 7 treated patients were classified as grade IIIb according to Clavien-Dindo scale. Post-surgical analysis of prostate tissue samples showed therapeutic pathomorphism of grade II in 3 patients (42.9 %), grade III in 1 patient (14.3 %) and grade IV in another patient (14.3 %). Urinary continence regained in all the patients. Average postoperative supervision period took 12 months. Disease progression was diagnosed in 1 patient (14.3 %).

Conclusion. Combined application of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy can be considered as an alternative method of treatment in a properly selected group of patients with oligo-metastatic prostate cancer.

1. Clinical cancer urology. Ed.: B.P. Matveev. Moskow: ABV-press, 2011. Pp. 566-734. (In Russ.).

2. Radical prostatectomy. Ed.: D.Yu. Pushkar. Moskow: GEOTAR-Media, 2011. Pp. 35-42. (In Russ.).

3. Grickevich A.A., Medvedev V.L., Kostin A.A., Rusakov I.G. Prognostic factors of survival rate in patients with prostate cancer. Eksperimental'naya i klinicheskaya urologiya = Experimental & Clinical Urology 2017;(4):12-19. (In Russ.). DOI: 10.29188/2222-8543.

4. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8.

5. Prostate cancer. Practical recommendations. Russian Society of Clinical Oncology. 2020. Avaliable at: https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-33.pdf. (In Russ.)

6. Clarke N.V., Ali A., Inglebi F.C. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: longterm survival results from the STAMPEDE trial. Ann Oncol 2019;30(12):1992-2003. DOI: 10.1093/annonc/mdz396.

7. Futterer J.J., Surcel C., van der Berg R. et al. Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol 2019;(37):2573-2583. DOI: 10.1007/s00345-018-2416-2.

8. Cho S.Y., Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med 2014;44(2):93-109. DOI: 10.1053/j.semnuclmed.2013.10.008.

9. Hellman S., Weichselbaum R.R. Oligometastases revisited. Nat Rev Clin Oncol 2011;(8):378-82. DOI: 10.1038/nrclinonc.2011.44.

10. Gandaglia G., Fosati N., Stabile A. et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 2017;72(2):289-92 DOI: 10.1016/j.eururo.2016.08.040.

11. Heidenreich A., Pfister D., Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015;193(3):832-8. DOI: 10.1016/j.juro.2014.09.089.

12. Culp S.H., Shellhammer P.F., Williams W.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66. DOI: 10.1016/j.eururo.2013.11.012.

13. Narasimhulu D.M., Khoyru-Collado F., Chi D.S. Radical surgery in ovarian cancer. Curr Oncol Rep 2015;17(4):16. DOI: 10.1007/s11912-015-0439-z.

14. Krabbe L.M., Haddad A.Q., Westerman M.E., Margulis V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol 2014;32(3):615-22. DOI: 10.1007/s00345-014-1286-5.

15. Faiena I., Singer E.A., Paumill C., Kim I.Y. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). Int J Oncol 2014;45(6):2193-8. DOI: 10.3892/ijo.2014.2656.

16. Jenjitranant P., Touijer K.A. Role of surgery in oligometastatic prostate cancer. Prostate Int 2019;7(4):125-30. DOI: 10.1016/j.prnil.2019.10.001.

17. Kadmon D., Heston W.D., Fair W.R. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 1982;127(6):1238-42. DOI: 10.1016/s0022-5347(17)54306-2.

18. Heidenreich A., Fossati N., Pfister D. et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol 2018;1(1):46-53. DOI: 10.1016/j.euo.2018.03.002.

19. Sooriakumaran P., Karnes J., Stief C. et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016;69(5):788-94. DOI: 10.1016/j.eururo.2015.05.023.

20. Berkut M.V., Artem'eva A.S., Reva S.A. et al. Oncological results of neoadjuvant chemogormonal therapy in patients with high and very high-risk prostate cancer. Onkourologya = Cancer Urology 2020;16(1):54-63. (In Russ.). DOI: 10.17650/1726-9776-2020-16-1-54-63.

21. Anton A., Hasan O.K., Ballok Z. et al. Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. BJU Int 2020;126(4):433-5. DOI: 10.1111/bju.15151.